Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Overview of attention for article published in The Lancet, November 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 8 news outlets
blogs: 5 blogs
policy: 4 policy sources
twitter: 24 X users
patent: 5 patents

facebook: 2 Facebook pages
wikipedia: 3 Wikipedia pages
googleplus: 1 Google+ user
linkedin: 1 LinkedIn user
f1000: 1 research highlight platform

Citations

dimensions_citation: 1032 Dimensions

Readers on

mendeley: 774 Mendeley

Summary News Blogs Policy documents X Patents Facebook Wikipedia Google+ LinkedIn Research highlights Dimensions citations

So far, Altmetric has seen 1 review on a research highlight platform.

Recommended in Faculty Opinions

11 Feb 2013

This research output was recommended by a member of Faculty Opinions.

This page shows the most recent research highlights that mention this research output.

Click here to find out how to access more activity.